Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)

F. Hoffmann-La Roche Ltd / Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• New and updated pivotal data from the TECENTRIQ lung programme, including overall survival (OS) and progression-free survival (PFS) results from Phase III IMpower133 study in extensive-stage small cell lung cancer

New integrated pivotal results for entrectinib in ROS1 fusion-positive non-small cell lung cancer, including the global Phase II STARTRK-2 basket study

Basel, 06 September 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its broad clinical development programme across different types of lung cancer will be presented at the International Association for the Study of Lung Cancer (IASLC) 2018 World Conference on Lung Cancer (WCLC), taking place from 23-26 September in Toronto, Canada. 10 abstracts have been accepted, including three 'late breakers' and five oral presentations.

"We look forward to presenting new data from our comprehensive lung cancer programme, including new immunotherapy and targeted treatment strategies across different types of lung cancer," said Sandra Horning, MD, Roche's Chief Medical Officer and Head of Global Product Development. "We are particularly pleased to be sharing positive TECENTRIQ data in extensive-stage small cell lung cancer, which has seen limited progress in treatment over the last two decades, as well as new pivotal data for our investigational therapy entrectinib for the treatment of ROS1 fusion-positive lung cancer."

Key presentations
Progression-free survival (PFS) and overall survival (OS) data from the Phase III IMpower133 study of TECENTRIQ plus chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES-SCLC) will be presented in the Presidential Symposium. These are the first positive survival data from a Phase III study with an immunotherapy-based combination in the initial treatment of ES-SCLC.